April 15, 2025.
Atmo Biosciences today announced the successful assignment of its foundational patent portfolio from RMIT University. Under this agreement, RMIT has transferred all patents and associated intellectual property (IP) related to the Atmo Gas Capsule to Atmo Biosciences in exchange for an equity stake in the company. This IP was previously subject to an exclusive royalty-based license agreement between Atmo and RMIT.
March 4, 2025.
Today, Atmo Biosciences announced the publication of pivotal clinical study data in Clinical Gastroenterology and Hepatology. The study validates the Atmo Capsule for assessing whole and regional gastrointestinal transit times to assist with the diagnosis of motility disorders such as gastroparesis and slow transit constipation.
14 October 2024.
Atmo Biosciences is pleased to announce that it has been awarded funding through the ANDHealth+ Stage 2 Commercialization Program, aimed at helping five digital health companies scale their products nationally and internationally.
May 2, 2024. Clinical Research.
Atmo Biosciences’ ingestible gas-sensing capsule was used to assess the impact of an early-time restricted eating diet on gastrointestinal hydrogen production and gastrointestinal transit time.
April 9, 2024.
Atmo Biosciences is delighted to report that it has successfully reached its primary endpoints in a pivotal clinical study to assess whole and regional gut transit time in subjects with suspected gastrointestinal motility disorders.
December 14, 2023.
Atmo Biosciences has reached its patient recruitment target ahead of schedule for its dysmotility pivotal clinical study.
More than 200 patients were recruited in a multi-site clinical trial to support a submission for initial U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders.
November 13, 2023.
Atmo Biosciences is pleased to announce that the Japan Patent Office has granted a patent related to key intellectual property for Atmo’s ingestible gas-sensing capsule.
October 26, 2023.
Atmo Biosciences today announced it is partnering with ps.healthcare to shape its data strategy, and create a roadmap of future applications using machine learning (ML) and artificial intelligence (AI).
October 19, 2023.
The Atmo Gas Capsule could be used to help understand and monitor duodeno-gastric reflux and provide insight into its connection to delayed gastric emptying, according to an investigation by researchers from Monash University and Western Sydney University.
October 3, 2023.
Atmo Biosciences has reached 60 per cent of its recruitment target for a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.
